476617-51-3
476617-51-3 結(jié)構(gòu)式
基本信息
Bayer 41-4109 less active enantiomer
BAY41-4109 LESS ACTIVE ENANTIOMER
BAY-41-4109 LESS ACTIVE ENANTIOMER
BAYER 41-4109 LESS ACTIVE ENANTIOMER
methyl (4S)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate
5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4S)-
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2023/03/20 | HY-100029B | 476617-51-3 Bay 41-4109 (less active enantiomer) | 476617-51-3 | 10mM * 1mLin DMSO | 2873元 |
| 2023/03/20 | HY-100029B | 476617-51-3 Bay 41-4109 (less active enantiomer) | 476617-51-3 | 5mg | 3300元 |
| 2023/03/20 | HY-100029B | 476617-51-3 Bay 41-4109 (less active enantiomer) | 476617-51-3 | 10mg | 5000元 |
常見問題列表
IC50: 53 nM (HBV, Bay 41-4109)
BAY 41-4109 is able to both accelerate and misdirect capsid assembly in vitro . Preformed capsids are stabilized by BAY 41-4109, up to a ratio of one inhibitor molecule per two dimers. BAY 41-4109 is equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with IC 50 s of 32.6 and 132 nM in HepG2.2.15 cells, respectively. HBV DNA and HBcAg are inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition.
BAY 41-4109 reduces viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC. BAY 41 -4109 reduces hepatitis B virus core antigen (HBcAg) in livers of HBV-transgenic mice. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations, about 60% in rats and dogs. BAY41-4109 inhibits virus production in vivo by a mechanism that targets the viral capsid.